Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:canBe |
gptkb:peripheral_neuropathy
osteoarthritis pain management |
| gptkbp:CASNumber |
gptkb:641571-10-0
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:drugClass |
FAAH inhibitor
|
| gptkbp:hasMolecularFormula |
C23H20F3N3O2
|
| gptkbp:IUPACName |
4-[2-(3-cyanopyridin-2-yl)-1H-indol-5-yl]-N-(2,2,2-trifluoroethyl)piperazine-1-carboxamide
|
| gptkbp:molecularWeight |
427.42 g/mol
|
| gptkbp:synonym |
gptkb:PF-04457845
|
| gptkbp:bfsParent |
gptkb:Tasigna
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
641571-10-0
|